SMS Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-20
Stock price
₹384.45
Market cap
3,600 Cr
Stock P/E
34.3
P/B
4.58
Dividend yield
0.1%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 Cr | 302 Cr | 463 Cr | 709 Cr | 164 Cr | 361 Cr | 173 Cr | 248 Cr | 196 Cr | 242 Cr | 210 Cr | 238 Cr |
| Operating expenses (approx.) | 109 Cr | 247 Cr | 378 Cr | 588 Cr | 130 Cr | 294 Cr | 140 Cr | 206 Cr | 156 Cr | 193 Cr | 163 Cr | 195 Cr |
| EBITDA | 27 Cr | 55 Cr | 86 Cr | 121 Cr | 35 Cr | 68 Cr | 33 Cr | 42 Cr | 40 Cr | 50 Cr | 47 Cr | 42 Cr |
| OPM % | 19.7% | 18.3% | 18.5% | 17.1% | 21.2% | 18.7% | 19.2% | 17.0% | 20.4% | 20.5% | 22.5% | 17.9% |
| Other income | 0.51 Cr | 1 Cr | 3 Cr | 4 Cr | 1 Cr | 3 Cr | 2 Cr | 1 Cr | 0.59 Cr | 1 Cr | 4 Cr | 3 Cr |
| Interest | 6 Cr | 12 Cr | 18 Cr | 23 Cr | 5 Cr | 9 Cr | 4 Cr | 5 Cr | 6 Cr | 6 Cr | 6 Cr | 5 Cr |
| Depreciation | 8 Cr | 16 Cr | 24 Cr | 32 Cr | 8 Cr | 17 Cr | 9 Cr | 9 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr |
| Profit before tax | 13 Cr | 28 Cr | 44 Cr | 66 Cr | 22 Cr | 41 Cr | 22 Cr | 29 Cr | 24 Cr | 34 Cr | 31 Cr | 27 Cr |
| Tax % | 30.5% | 25.1% | 25.3% | 25.6% | 25.0% | 26.9% | 23.9% | 29.6% | 23.2% | 26.2% | 25.6% | 22.5% |
| Net profit | 9 Cr | 21 Cr | 33 Cr | 50 Cr | 16 Cr | 31 Cr | 18 Cr | 20 Cr | 20 Cr | 25 Cr | 23 Cr | 33 Cr |
| EPS (₹) | ₹1.10 | ₹2.49 | ₹3.84 | ₹5.89 | ₹1.95 | ₹3.61 | ₹2.15 | ₹2.40 | ₹2.31 | ₹2.84 | ₹2.59 | ₹3.58 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 465 Cr | 412 Cr | 563 Cr | 520 Cr | 522 Cr | 709 Cr | 783 Cr | 887 Cr | Sign in for TTM |
| Operating expenses (approx.) | 375 Cr | 327 Cr | 439 Cr | 400 Cr | 468 Cr | 593 Cr | 638 Cr | 707 Cr | Sign in for TTM |
| EBITDA | 90 Cr | 85 Cr | 125 Cr | 120 Cr | 55 Cr | 117 Cr | 145 Cr | 180 Cr | Sign in for TTM |
| OPM % | 19.4% | 20.6% | 22.1% | 23.0% | 10.4% | 16.4% | 18.6% | 20.3% | Sign in for TTM |
| Other income | 3 Cr | 5 Cr | 3 Cr | 5 Cr | 5 Cr | 4 Cr | 6 Cr | 8 Cr | Sign in for TTM |
| Interest | 12 Cr | 12 Cr | 11 Cr | 19 Cr | 22 Cr | 23 Cr | 19 Cr | 23 Cr | Sign in for TTM |
| Depreciation | 19 Cr | 22 Cr | 22 Cr | 32 Cr | 32 Cr | 32 Cr | 34 Cr | 40 Cr | Sign in for TTM |
| Profit before tax | 62 Cr | 51 Cr | 91 Cr | 68 Cr | 5 Cr | 66 Cr | 92 Cr | 117 Cr | Sign in for TTM |
| Tax % | 14.3% | 35.6% | 33.1% | 0.9% | 27.4% | 25.6% | 27.0% | 24.6% | Sign in for TTM |
| Net profit | 53 Cr | 33 Cr | 63 Cr | 62 Cr | -7 Cr | 50 Cr | 69 Cr | 102 Cr | Sign in for TTM |
| EPS (₹) | ₹4.90 | ₹3.73 | ₹7.39 | ₹7.35 | ₹-0.83 | ₹5.89 | ₹8.16 | ₹11.15 | Sign in for TTM |
| Dividend payout % | — | — | — | 4.1% | — | 5.1% | 4.9% | 3.5% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 8 Cr | 9 Cr | 9 Cr |
| Reserves | 331 Cr | 340 Cr | 402 Cr | 0.0000 Cr | 452 Cr | 528 Cr | 631 Cr | 776 Cr |
| Borrowings | 130 Cr | — | — | — | 253 Cr | 280 Cr | 171 Cr | 193 Cr |
| Other liabilities | 107 Cr | — | — | — | 167 Cr | 218 Cr | 342 Cr | 383 Cr |
| Total liabilities | 577 Cr | — | — | — | 880 Cr | 1,034 Cr | 1,153 Cr | 1,362 Cr |
| Fixed assets (net) | 280 Cr | — | — | — | 409 Cr | 434 Cr | 531 Cr | 531 Cr |
| CWIP | 18 Cr | — | — | — | 33 Cr | 30 Cr | 35 Cr | 122 Cr |
| Investments | 19 Cr | — | — | — | 11 Cr | 11 Cr | 12 Cr | 26 Cr |
| Other assets | 208 Cr | — | — | — | 411 Cr | 534 Cr | 554 Cr | 638 Cr |
| Total assets | 577 Cr | — | — | — | 880 Cr | 1,034 Cr | 1,153 Cr | 1,362 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 40 Cr | 22 Cr | 50 Cr | 82 Cr | 59 Cr |
| Cash from investing | — | — | — | -27 Cr | -30 Cr | -52 Cr | -123 Cr | -131 Cr |
| Cash from financing | — | — | — | -7 Cr | -32 Cr | 31 Cr | 47 Cr | 76 Cr |
| Net cash flow | — | — | — | 6 Cr | -39 Cr | 29 Cr | 5 Cr | 4 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 13 Cr | -7 Cr | -2 Cr | -42 Cr | -71 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 15.1% | 18.1% | 24.9% | 1032.2% | 3.1% | 10.4% | 13.7% | 14.3% |
| ROE % | 15.7% | 0.0% | 15.2% | 0.0% | 0.0% | 0.0% | 10.7% | 13.0% |
| Debtor days | 20 | — | — | — | 103 | 122 | — | — |
| Inventory days | 162 | — | — | — | 271 | 201 | 207 | 248 |
| Days payable | 0 | — | — | — | 137 | 130 | — | — |
| Cash conversion cycle | 182 | — | — | — | 237 | 192 | 207 | 248 |
| Debt / equity | 0.38 | 0.00 | — | — | 0.55 | 0.52 | 0.27 | 0.25 |
| Current ratio | 1.42 | — | — | — | 1.61 | 1.61 | 1.71 | 1.81 |
| Net debt / EBITDA | 1.28 | 0.00 | 0.00 | 0.00 | 4.50 | 2.09 | 0.90 | 0.82 |
Compare with peers
Loading peers…